RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 2961-2973

  Danhier, Fabienne ^a   Breton, Aude Le ^a   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

alpha(v) beta(3) integrin; angiogenesis; cancer diagnosis; cancer therapy; nanoparticles; RGD; tumor vasculature

Indexed keywords

AH 111585; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTYL FLUOROMETHYL KETONE; CILENGITIDE; DOXORUBICIN; DY 615; ENDOSTATIN; ETARACIZUMAB; GELDANAMYCIN; GLYCYLARGINYLGLYCYLASPARTYLSERINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA ANTIBODY; INTERLEUKIN 12; MARACICLATIDE; MELPHALAN; MICRORNA 296 ANITBODY; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PLXDC1 PROTEIN; S 137; S 247; SMALL INTERFERING RNA; TECHNETIUM 99M; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL ADHESION; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG SAFETY; GENE OVEREXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SURVIVAL TIME;

HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASMS; OLIGOPEPTIDES; RADIOPHARMACEUTICALS;

EID: 84868563717     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3002733     Document Type: Article

References (106)

1. Folkman, J. Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 1971, 285, 1182-1186
2. Nussenbaum, F.; Herman, I. M. Tumor angiogenesis: insights and innovations J. Oncol. 2010, 2010, 132641
3. Jain, R. K. Transport of molecules in the tumor interstitium: a review Cancer Res. 1987, 47, 3039-3051
4. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis Nat. Med. 2000, 6, 389-395
5. Francavilla, C.; Maddaluno, L.; Cavallaro, U. The functional role of cell adhesion molecules in tumor angiogenesis Semin. Cancer Biol. 2009, 19, 298-309
6. Naumov, G. N.; Akslen, L. A.; Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch Cell Cycle 2006, 5, 1779-1787
7. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 2010, 10, 9-22
8. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in angiogenesis and lymphangiogenesis Nat. Rev. Cancer 2008, 8, 604-617
9. Barczyk, M.; Carracedo, S.; Gullberg, D. Integrins Cell Tissue Res. 2010, 339, 269-280
10. Giancotti, F. G.; Ruoslahti, E. Integrin signaling Science 1999, 285, 1028-1032
11. Hsu, A. R.; Veeravagu, A.; Cai, W.; Hou, L. C.; Tse, V.; Chen, X. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment Recent Pat. Anti-Cancer Drug Discovery 2007, 2, 143-158
12. Switala-Jelen, K.; Dabrowska, K.; Opolski, A.; Lipinska, L.; Nowaczyk, M.; Gorski, A. The biological functions of beta3 integrins Folia Biol. (Praha) 2004, 50, 143-152
13. Brooks, P. C.; Clark, R. A.; Cheresh, D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 1994, 264, 569-571
14. Hodivala-Dilke, K. M.; Reynolds, A.; Reynolds, L. Integrins in angiogenesis: multitalented molecules in a balancing act Cell Tissue Res. 2003, 314, 131-44
15. Echarri, A.; Del Pozo, M. Caveolae internalization regulates integrin-dependent signaling pathways Cell Cycle 2006, 19, 2179-2182
16. Ramsey, A.; Marshall, J.; Hart, I. Integrin trafficking and its role in cancer metastasis Cancer Metastasis Rev. 2007, 26, 567-578
17. Reynolds, A. R.; Hart, I.; Watson, A.; Welti, J.; Silva, R.; Robinson, S.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M.; Jones, D.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J.; Tucker, G.; Hodivala-Dilke, K. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat. Med. 2009, 15, 392-400
18. Takayama, S.; Ishii, S.; Ikeda, T.; Masamura, S.; Doi, M.; Kitajima, M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression Anticancer Res. 2005, 25, 79-83
19. Furger, K. A.; Allan, A. L.; Wilson, S. M.; Hota, C.; Vantyghem, S. A.; Postenka, C. O.; Al-Katib, W.; Chambers, A. F.; Tuck, A. B. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin Mol. Cancer Res. 2003, 1, 810-819
20. Vellon, L.; Menendez, J. A.; Liu, H.; Lupu, R. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner Differentiation 2007, 75, 819-830
21. Sheldrake, H. M.; Patterson, L. H. Function and antagonism of beta3 integrins in the development of cancer therapy Curr. Cancer Drug Targets 2009, 9, 519-540
22. Hosotani, R.; Kawaguchi, M.; Masui, T.; Koshiba, T.; Ida, J.; Fujimoto, K.; Wada, M.; Doi, R.; Imamura, M. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis Pancreas 2002, 25, e30-e35
23. Marinelli, L.; Lavecchia, A.; Gottschalk, K. E.; Novellino, E.; Kessler, H. Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design J. Med. Chem. 2003, 46, 4393-4404
24. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins Science 1987, 238, 491-497
25. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature Drug Resist. Updates 2005, 8, 381-402
26. Liu, S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging Mol. Pharmaceutics 2006, 3, 472-487
27. Gaertner, F.; Kessler, H.; Wester, H.; Schwaiger, M.; Beer, A. Radiolabelled RGD peptides for imaging and therapy Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S126-S138
28. Shannon, K. E.; Keene, J. L.; Settle, S. L.; Duffin, T. D.; Nickols, M. A.; Westlin, M.; Schroeter, S.; Ruminski, P. G.; Griggs, D. W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247 Clin. Exp. Metastasis 2004, 21, 129-38
29. Rerat, V.; Dive, G.; Cordi, A. A.; Tucker, G. C.; Bareille, R.; Amedee, J.; Bordenave, L.; Marchand-Brynaert, J. alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers J. Med. Chem. 2009, 52, 7029-7043
30. Yamada, S.; Bu, X. Y.; Khankaldyyan, V.; Gonzales-Gomez, I.; McComb, J. G.; Laug, W. E. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice Neurosurgery 2006, 59 (6) 1304-1312
31. ODonnell, P. H.; Undevia, S. D.; Stadler, W. M.; Karrison, T. M.; Nicholas, M. K.; Janisch, L.; Ratain, M. J. A phase I study of continuous infusion cilengitide in patients with solid tumors Invest. New Drugs 2012, 30, 604-610
32. Alva, A.; Slovin, S.; Daignault, S.; Carducci, M.; Dipaola, R.; Pienta, K.; Agus, D.; Cooney, K.; Chen, A.; Smith, D. C.; Hussain, M. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium Invest. New Drugs 2012, 30, 749-757
33. Carter, A. Integrins as target: first phase III trial launches, but questions remain J. Natl. Cancer Inst. 2010, 102, 675-677
34. Fink, K.; Mikkelsen, T.; Nabors, L. B.; Ravin, P.; Plotkin, S. R.; Schiff, D.; Hicking, C.; Picard, M.; Reardon, D. A. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study J. Clin. Oncol. 2010, 28, 182s
35. Albert, J. M.; Cao, C.; Geng, L.; Leavitt, L.; Hallahan, D. E.; Lu, B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 1536-1543
36. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. Phase I/IIa study of cilengitide and Temozolomide with concomitant radiotherapy followed by cilengitide and Temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J. Clin. Oncol. 2010, 28, 2712-2718
37. Reinmuth, N.; Liu, W.; Ahmad, S. A.; Fan, F.; Stoeltzing, O.; Parikh, A. A.; Bucana, C. D.; Gallick, G. E.; Nickols, M. A.; Westlin, W. F.; Ellis, L. M. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice Cancer Res. 2003, 63, 2079-2087
38. Shannon, K. E.; Keene, J. L.; Settle, S. L.; Duffin, T. D.; Nickols, M. A.; Westlin, M.; Schroeter, S.; Ruminski, P. G.; Griggs, D. W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247 Clin. Exp. Metastasis 2004, 21, 129-138
39. Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Da, V. G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J. C.; Tucker, G. C.; Hodivala-Dilke, K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat. Med. 2009, 15, 392-400
40. Raguse, J. D.; Gath, H. J.; Bier, J.; Riess, H.; Oettle, H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour Oral Oncol. 2004, 40, 228-230
41. Reynolds, L. E.; Wyder, L.; Lively, J. C.; Taverna, D.; Robinson, S. D.; Huang, X.; Sheppard, D.; Hynes, R. O.; Hodivala-Dilke, K. M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins Nat. Med. 2002, 8, 27-34
42. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Controlled Release 2001, 74, 47-61
43. Malam, Y.; Loizidou, M.; Seifalian, A. M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer Trends Pharmacol. Sci. 2009, 30, 592-599
44. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Delivery Rev. 2008, 60, 1615-1626
45. Zitzmann, S.; Ehemann, V.; Schwab, M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo Cancer Res. 2002, 62, 5139-5143
46. Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Controlled Release 2010, 148, 135-146
47. Murphy, E. A.; Majeti, B. K.; Barnes, L. A.; Makale, M.; Weis, S. M.; Lutu-Fuga, K.; Wrasidlo, W.; Cheresh, D. A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9343-9348
48. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel J. Controlled Release 2009, 140, 166-173
49. Danhier, F.; Pourcelle, V.; Marchand-Brynaert, J.; Jérôme, C.; Feron, O.; Préat, V. Targeting of Tumor Endothelium by RGD-Grafted PLGA-Nanoparticles Methods Enzymol. 2012, 508, 157-175
50. Xu, W.; Luo, T.; Li, P.; Zhou, C.; Cui, D.; Pang, B.; Ren, Q.; Fu, S. RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating alpha(v)beta expression Int. J. Nanomed. 2012, 7, 915-924
51. Zhan, C.; Gu, B.; Xie, C.; Li, J.; Liu, Y.; Lu, W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect J. Controlled Release 2010, 143, 136-142
52. Borgman, M. P.; Aras, O.; Geyser-Stoops, S.; Sausville, E. A.; Ghandehari, H. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery Mol. Pharmaceutics 2009, 6, 1836-1847
53. Meng, S.; Su, B.; Li, W.; Ding, Y.; Tang, L.; Zhou, W.; Song, Y.; Caicun, Z. Integrin-targeted paclitaxel nanoliposomes for tumor therapy Med. Oncol. 2011, 28 (4) 1180-1187
54. Curnis, F.; Gasparri, A.; Sacchi, A.; Longhi, R.; Corti, A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity Cancer Res. 2004, 64, 565-571
55. Cao, L.; Du, P.; Jiang, S. H.; Jin, G. H.; Huang, Q. L.; Hua, Z. C. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature Mol. Cancer Ther. 2008, 7, 851-861
56. Xu, H. M.; Yin, R.; Chen, L.; Siraj, S.; Huang, X.; Wang, M.; Fang, H.; Wang, Y. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo Bioconjugate Chem. 2008, 19, 1980-1986
57. Dickerson, E. B.; Akhtar, N.; Steinberg, H.; Wang, Z. Y.; Lindstrom, M. J.; Padilla, M. L.; Auerbach, R.; Helfand, S. C. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin Mol. Cancer Res. 2004, 2, 663-673
58. Gao, Y.; Liu, X. L.; Li, X. R. Research progress on siRNA delivery with nonviral carriers Int. J. Nanomed. 2011, 6, 1017-1025
59. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Woodle, M. C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 2004, 32, e149
60. Han, H. D.; Mangala, L. S.; Lee, J. W.; Shahzad, M. M.; Kim, H. S.; Shen, D.; Nam, E. J.; Mora, E. M.; Stone, R. L.; Lu, C.; Lee, S. J.; Roh, J. W.; Nick, A. M.; Lopez-Berestein, G.; Sood, A. K. Targeted gene silencing using RGD-labeled chitosan nanoparticles Clin. Cancer Res. 2010, 16, 3910-3922
61. Numata, K.; Hamasaki, J.; Subramanian, B.; Kaplan, D. L. Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs J. Controlled Release 2010, 146, 136-143
62. Jiang, J.; Yang, S. J.; Wang, J. C.; Yang, L. J.; Xu, Z. Z.; Yang, T.; Liu, X. Y.; Zhang, Q. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin Eur. J. Pharm. Biopharm. 2010, 76, 170-178
63. Alam, M. R.; Dixit, V.; Kang, H.; Li, Z. B.; Chen, X.; Trejo, J.; Fisher, M.; Juliano, R. L. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis Nucleic Acids Res. 2008, 36, 2764-2776
64. Chou, S. T.; Leng, Q.; Scaria, P.; Woodle, M.; Mixson, A. J. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo Cancer Gene Ther. 2011, 18, 707-716
65. Wang, X. L.; Xu, R.; Wu, X.; Gillespie, D.; Jensen, R.; Lu, Z. R. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice Mol. Pharmaceutics 2009, 6, 738-746
66. Liu, X. Q.; Song, W. J.; Sun, T. M.; Zhang, P. Z.; Wang, J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles Mol. Pharmaceutics 2011, 8, 250-259
67. Abdollahi, A.; Griggs, D. W.; Zieher, H.; Roth, A.; Lipson, K. E.; Saffrich, R.; Grone, H. J.; Hallahan, D. E.; Reisfeld, R. A.; Debus, J.; Niethammer, A. G.; Huber, P. E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy Clin. Cancer Res. 2005, 11, 6270-6279
68. Fani, M.; Maecke, H. R.; Okarvi, S. M. Radiolabeled peptides: valuable tools for the detection and treatment of cancer Theranostics 2012, 2, 481-501
69. Janssen, M. L.; Frielink, C.; Dijkgraaf, I.; Oyen, W. J.; Edwards, D. S.; Liu, S.; Rajopadhye, M.; Massuger, L. F.; Corstens, F. H.; Boerman, O. C. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation Cancer Biother. Radiopharm. 2004, 19, 399-404
70. Mitra, A.; Nan, A.; Ghandehari, H.; McNeill, E.; Mulholland, J.; Line, B. R. Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution Pharm. Res. 2004, 21, 1153-1159
71. Lee, J. H.; Lee, K.; Moon, S. H.; Lee, Y.; Park, T. G.; Cheon, J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery Angew. Chem., Int. Ed. 2009, 48, 4174-4179
72. Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Nanotheranostics and image-guided drug delivery: current concepts and future directions Mol. Pharmaceutics 2010, 7, 1899-1912
73. Pike, D. B.; Ghandehari, H. HPMA copolymer-cyclic RGD conjugates for tumor targeting Adv. Drug Delivery Rev. 2010, 62, 167-183
74. Nasongkla, N.; Bey, E.; Ren, J.; Ai, H.; Khemtong, C.; Guthi, J. S.; Chin, S. F.; Sherry, A. D.; Boothman, D. A.; Gao, J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems Nano Lett. 2006, 6, 2427-2430
75. Schmieder, A. H.; Caruthers, S. D.; Zhang, H.; Williams, T. A.; Robertson, J. D.; Wickline, S. A.; Lanza, G. M. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J. 2008, 22, 4179-4189
76. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Girard, O. M.; Hanahan, D.; Mattrey, R. F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors Cancer Cell 2009, 16, 510-520
77. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 2010, 328, 1031-1035
78. Beer, A. J.; Schwaiger, M. Imaging of integrin alphavbeta3 expression Cancer Metastasis Rev. 2008, 27, 631-644
79. Ye, Y.; Chen, X. integrin targeting for tumor optical imaging Theranostics 2011, 1, 103-125
80. Haubner, R.; Wester, H. J.; Weber, W. A.; Mang, C.; Ziegler, S. I.; Goodman, S. L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 2001, 61, 1781-1785
81. Beer, A. J.; Grosu, A.; Carlsen, J. [18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin. Cancer Res. 2007, 13, 6610-6616
82. Chen, X.; Conti, P. S.; Moats, R. A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts Cancer Res. 2004, 64, 8009-8014
83. Wang, W.; Ke, S.; Wu, Q.; Charnsangavej, C.; Gurfinkel, M.; Gelovani, J. G. Near-infrared optical imaging of integrin αvβ3 in human tumor xenografts Mol. Imaging 2004, 3, 343-351
84. Li, C.; Wang, W.; Wu, Q.; Ke, S.; Houston, J.; Sevick-Muraca, E. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe Nucl. Med. Biol. 2006, 33, 349-358
85. Bach-Gansmo, T.; Danielsson, R.; Saracco, A.; Wilczek, B.; Bogsrud, T. V.; Fangberget, A.; Tangerud, A.; Tobin, D. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692 J. Nucl. Med. 2006, 47, 1434-1439
86. Dijkgraaf, I.; Boerman, O. C. Radionuclide imaging of tumor angiogenesis Cancer Biother. Radiopharm. 2009, 24, 637-647
87. Liu, S.; Hsieh, W. Y.; Jiang, Y.; Kim, Y. S.; Sreerama, S. G.; Chen, X.; Jia, B.; Wang, F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer Bioconjugate Chem. 2007, 18, 438-446
88. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P.; Hui, A.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J. Nucl. Med. 2008, 49, 879-86
89. Haubner, R.; Weber, W.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.; Goebel, M.; Hein, R.; Wester, H.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD PLoS Med. 2005, 2, e70
90. Hu, G.; Lijowski, M.; Zhang, H.; Partlow, K. C.; Caruthers, S. D.; Kiefer, G.; Gulyas, G.; Athey, P.; Scott, M. J.; Wickline, S. A.; Lanza, G. M. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles Int. J. Cancer 2007, 120, 1951-1957
91. Sipkins, D. A.; Cheresh, D. A.; Kazemi, M. R.; Nevin, L. M.; Bednarski, M. D.; Li, K. C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging Nat. Med 1998, 4, 623-626
92. Schmieder, A. H.; Winter, P. M.; Caruthers, S. D.; Harris, T. D.; Williams, T. A.; Allen, J. S.; Lacy, E. K.; Zhang, H.; Scott, M. J.; Hu, G.; Robertson, J. D.; Wickline, S. A.; Lanza, G. M. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles Magn Reson. Med. 2005, 53, 621-627
93. Rosen, J. E.; Chan, L.; Shieh, D. B.; Gu, F. X. Iron oxide nanoparticles for targeted cancer imaging and diagnostics Nanomedicine 2012, 8 (3) 275-290
94. Zhang, C.; Jugold, M.; Woenne, E. C.; Lammers, T.; Morgenstern, B.; Mueller, M. M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner Cancer Res. 2007, 67, 1555-1562
95. Xie, J.; Chen, K.; Lee, H. Y.; Xu, C.; Hsu, A. R.; Peng, S.; Chen, X.; Sun, S. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells J. Am. Chem. Soc. 2008, 130, 7542-7543
96. Kiessling, F.; Huppert, J.; Zhang, C.; Jayapaul, J.; Zwick, S.; Woenne, E. C.; Mueller, M. M.; Zentgraf, H.; Eisenhut, M.; Addadi, Y.; Neeman, M.; Semmler, W. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment Radiology 2009, 253, 462-469
97. Cai, W.; Shin, D. W.; Chen, K.; Gheysens, O.; Cao, Q.; Wang, S. X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects Nano Lett. 2006, 6, 669-676
98. Wang, M.; Thanou, M. Targeting nanoparticles to cancer Pharmacol. Res. 2010, 62, 90-99
99. Prokop, A.; Davidson, J. M. Nanovehicular intracellular delivery systems J. Pharm. Sci. 2008, 97, 3518-3590
100. Nam, H. Y.; Kwon, S. M.; Chung, H.; Lee, S. Y.; Kwon, S. H.; Jeon, H.; Kim, Y.; Park, J. H.; Kim, J.; Her, S.; Oh, Y. K.; Kwon, I. C.; Kim, K.; Jeong, S. Y. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles J. Controlled Release 2009, 135, 259-267
101. Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines J. Controlled Release 2010, 145, 182-195
102. Duggan, M. E.; Duong, L. T.; Fisher, J. E.; Hamill, T. G.; Hoffman, W. F.; Huff, J. R. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist J. Med. Chem. 2000, 43, 3736-3745
103. Pastorino, F.; Brignole, C.; Di, P. D.; Nico, B.; Pezzolo, A.; Marimpietri, D.; Pagnan, G.; Piccardi, F.; Cilli, M.; Longhi, R.; Ribatti, D.; Corti, A.; Allen, T. M.; Ponzoni, M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy Cancer Res. 2006, 66, 10073-10082
104. Daniels, T. R.; Delgado, T.; Helguera, G.; Penichet, M. L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells Clin. Immunol. 2006, 121 (2) 159-176
105. Misra, R.; Acharya, S.; Sahoo, S. K. Cancer nanotechnology: application of nanotechnology in cancer therapy Drug Discovery Today 2010, 15, 842-850
106. Bouzin, C.; Feron, O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery Drug Resist. Updates 2007, 10, 109-120